Nearly a Third of COPD Hospital Costs May Be Avoidable, Iranian Study Finds

Chronic obstructive pulmonary disease, or COPD, is one of the world’s most burdensome lung conditions, and the moment its trajectory tips into an acute exacerbation—a sudden flare of breathlessness, cough, and mucus that forces patients into hospital—the economics of the disease change dramatically. A new retrospective study from Shiraz, Iran, has put hard numbers on that economic tipping point, and the results carry a message that resonates far beyond one city: a large slice of what health systems spend treating these crises may never have needed to be spent at all.

Researchers at Shiraz University of Medical Sciences examined the records of 150 patients hospitalized with acute exacerbations of COPD, known clinically as AECOPD, at Shahid Faqihi Hospital in 2024. Their goal was to untangle three questions that health economists rarely get to answer simultaneously in one dataset: how much these admissions actually cost under official hospital tariffs, what happened to the patients clinically, and which of the services billed during the stay were potentially avoidable in the first place. Using a data extraction checklist refined with clinical experts, the team compiled demographic details, treatment outcomes, direct medical expenditures, and a category of spending they classified as avoidable healthcare expenditure.

The headline figure is striking. The mean tariff-based direct medical cost per patient came to $2,620, a substantial sum in any health system but particularly significant in Iran, where hospital reimbursement rates are set by national tariffs and resources are under sustained pressure. Yet when the researchers applied criteria for avoidable services, they estimated that an average of $754 per patient—close to 29 percent of the total bill—fell into the avoidable category. In other words, for roughly every three dollars spent treating a hospitalized COPD exacerbation in this cohort, one dollar may have been spent on care that better adherence to evidence-based guidelines could have trimmed or eliminated.

Where did that avoidable money go? Intensive care dominated the list, accounting for $558 of the $754 average avoidable expenditure, followed by the costs of hospitalization itself at $159, lung computed tomography scans at $28, and antibiotics at just $9. The distribution is telling. Antibiotic overuse, often the first thing clinicians and policy experts worry about in exacerbation care, turns out to be a minor financial issue here compared with ICU admissions and prolonged ward stays. The pattern suggests that the biggest levers for savings are not marginal drug choices but the major decisions: whether a patient needs critical care, how long they occupy a bed, and whether high-cost imaging is truly indicated.

That lung CT scans appear on the avoidable list is worth dwelling on, because it speaks to a wider and well-documented phenomenon. Acute exacerbations of COPD are diagnosed clinically, and routine CT imaging of the lungs during a flare-up adds expense and radiation exposure without typically changing immediate management. The study describes a category of CT scan prescriptions triggered by lung X-ray findings, and the authors’ inclusion of imaging among avoidable costs implies that some of this diagnostic cascade proceeded without clear justification. Health systems worldwide have wrestled with similar imaging overuse, and the Shiraz data offer a concrete, quantified example of what that overuse costs in real money terms.

The clinical outcomes in the cohort provide sobering context for the cost figures. Most patients, 80.6 percent, were discharged after recovery, but 7.3 percent required ICU admission and 10.7 percent died during hospitalization. A mortality rate of roughly one in ten hospitalized exacerbation patients underscores that these admissions are genuinely high-stakes events, not routine managed care. The challenge the study frames is therefore not to stint on genuinely necessary intensive treatment but to prevent the disease from reaching the point where such treatment becomes necessary—through better outpatient management, earlier intervention, and tighter guideline adherence.

Most patients in the study, 76 percent, experienced no more than two exacerbations per year, which aligns with the typical epidemiology of COPD, where a subset of frequent exacerbators drives a disproportionate share of the burden. The cohort was predominantly male, at 70.7 percent, reflecting patterns of smoking and occupational exposure common in the region, and 81.3 percent had at least one comorbidity. That heavy comorbidity load is central to the study’s cost analysis, because coexisting conditions complicate both the course of an exacerbation and the decisions clinicians make about testing and admission.

When the team ran multiple linear regression to identify which factors independently predicted higher total medical costs, three predictors emerged: longer hospital stay, the presence of cerebrovascular disease, and the use of medications other than standard COPD therapies. The first is almost tautological—each additional day in hospital accrues charges—but it is also the most actionable, since reducing length of stay through efficient, guideline-concordant care directly lowers cost. The second highlights how stroke and related vascular disease amplify the expense of COPD flares, likely through longer and more complicated admissions. The third is the most provocative: deviation from standard COPD pharmacotherapy, whether through unnecessary additions or substitutions, was independently associated with higher spending, hinting that off-guideline prescribing is not just a quality issue but a measurable cost driver.

To check that their avoidable-cost estimates were not artifacts of arbitrary assumptions, the researchers performed a one-way sensitivity analysis, a standard health-economic technique that varies key inputs to see whether conclusions hold. The robustness of the estimated avoidable expenditure under this analysis strengthens the central claim that a meaningful fraction of AECOPD spending is discretionary. Analyses were conducted in SPSS version 23 and Microsoft Excel, with t-tests and analysis of variance used alongside the regression models to compare subgroups.

The study, published in BMC Health Services Research and funded by Shiraz University of Medical Sciences, arrives with clear implications. Hospitalization for acute COPD exacerbation imposes substantial expenditure, and hospitalization, ICU care, and lung CT scans together account for a considerable proportion of what the authors deem avoidable. Their prescription is straightforward: improve adherence to evidence-based clinical guidelines, and health systems can reduce avoidable services while allocating scarce resources more efficiently. For a disease projected to keep climbing in global prevalence as populations age and smoking legacies persist, the Shiraz findings offer a template other hospitals in low- and middle-income settings could replicate—measuring not just what care costs, but what care should never have cost in the first place.

Subject of Research: Healthcare costs and avoidable services in hospitalized patients with acute exacerbations of COPD in Iran

Article Title: Costs, outcomes, and avoidable services in hospitalized patients with acute exacerbations of COPD: a retrospective analysis from Shiraz, Iran

Article References: Costs, outcomes, and avoidable services in hospitalized patients with acute exacerbations of COPD: a retrospective analysis from Shiraz, Iran. (n.d.). https://doi.org/10.1186/s12913-026-15833-z

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15833-z

Keywords: COPD, AECOPD, hospitalization costs, avoidable services, health economics, ICU care, lung CT scans, clinical guidelines, Iran, health services research, treatment outcomes, hospital tariffs